Role of Trimetazidine in Management of Ischemic Cardiomyopathy

American Journal of Cardiology

Volumn 98, Issue 5 SUPPL. 1, 2006, Pages 19-24

  Bertomeu Gonzalez, Vicente ^a   Bouzas Mosquera, Alberto ^a   Kaski, Juan Carlos ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; TRIMETAZIDINE;

ARTICLE; CLINICAL TRIAL; ENDOTHELIUM; EXERCISE TEST; HEALTH STATUS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; SYMPTOM;

HUMANS; MYOCARDIAL ISCHEMIA; STROKE VOLUME; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 33747342120     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.005     Document Type: Article

References (23)

1. Katz A.M. Heart Failure. Pathophysiology, Molecular Biology and Clinical Management (2000), Lippincott Williams & Wilkins, Philadelphia
2. Braunwald E., and Rutherford J.D. Reversible ischemic left ventricular dysfunction. evidence for the "hibernating myocardium.". J Am Coll Cardiol 8 (1986) 1467-1470
3. Cooper H.A., and Braunwald E. Clinical importance of stunned and hibernating myocardium. Coron Artery Dis 12 (2001) 387-392
4. Stanley W.C., Recchi F.A., and Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85 (2005) 1093-1129
5. Szwed H., Pachocki R., Domzal-Bochenska M., Szydlowski Z., Paradowski A., Gajos G., Kaluza G., Kulon I., Wator-Brzezinska A., Elikowski W., and Kuzniak M. Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. [in French]. Presse Med 29 (2000) 533-538
6. Szwed H., Sadowski Z., Elikowski W., Koronkiewicz A., Mamcarz A., Orszulak W., Skibinska E., Szymczak K., Swiatek J., and Winter M. Combination treatment in stable effort angina using trimetazidine and metoprolol. results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J 24 (2001) 2267-2274
7. Kantor P.F., Lucien A., Kozak R., and Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86 (2000) 580-588
8. Mody F.V., Singh B.N., Mohiuddin I.H., Coyle K.B., Buxton D.B., Hansen H.W., Sumida R., and Schelbert H.R. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue. an evaluation by positron emission tomography. Am J Cardiol 82 suppl (1998) 42K-49K
9. Ruzyllo W., Szwed H., Sadowski Z., Elikowski W., Grzelak-Szafranska H., Orszulak W., Szymczak K., and Winter M. Efficacy of trimetazidine in patients with recurrent angina. a subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 20 (2004) 1447-1454
10. Brottier L., Barat J.L., Combe C., Boussens B., Bonnet J., and Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 11 (1990) 207-212
11. Vitale C., Wajngaten M., Sposato B., Gebara O., Rossini P., Fini M., Volterrani M., and Rosano G.M. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 25 (2004) 1814-1821
12. Fragasso G., Piatti P.M., Monti L., Palloshi A., Setola E., Puccetti P., Calori G., Lopaschuk G.D., and Margonato A. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 146 (2003) E18-E25
13. Di Napoli P., Taccardi A.A., and Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 91 (2005) 161-165
14. El-Kady T., El-Sabban K., Gabaly M., Sabry A., and Abdel-Hady S. Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy. a 24-month study. Am J Cardiovasc Drugs 5 (2005) 271-278
15. Rosano G.M., Vitale C., Sposato B., Mercuro G., and Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease. a double-blind placebo-controlled study. Cardiovasc Diabetol 2 (2003) 16
16. Belardinelli R., and Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 22 (2001) 2164-2170
17. Lu C., Dabrowski P., Fragasso G., and Chierchia S.L. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 82 (1998) 898-901
18. Romano M., Spinelli R., Russo L., Di Iaconi E., Lerro A., Meccariello P., Carlomagno A., and Muto P. Trimetazidine in patients with previous myocardial revascularization and left ventricular dysfunction. an exercise stress testing and radionuclide study. [in Italian]. Italian Journal of Cardiology Practice (2003) 29-36
19. Avanzas P., Arroyo-Espliguero R., Cosin-Sales J., Quiles J., Zouridakis E., and Kaski J.C. Multiple complex stenoses, high neutrophil count and C-reactive protein levels in patients with chronic stable angina. Atherosclerosis 175 (2004) 151-157
20. Arroyo-Espliguero R., Avanzas P., Cosin-Sales J., Aldama G., Pizzi C., and Kaski J.C. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 25 (2004) 401-408
21. Zouridakis E., Avanzas P., Arroyo-Espliguero R., Fredericks S., and Kaski J.C. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 110 (2004) 1747-1753
22. Kaski J.C., and Garcia-Moll X. C-reactive protein as a clinical marker of risk. Circulation 102 (2000) E63-E64
23. Monti L.D., Setola E., Fragasso G., Camisasca R.P., Lucotti P., Galluccio E., Origgi E., Margonato A., and Piatti P. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab 290 (2006) E54-E59